iBio, Inc.
NASDAQ:IBIOBiotechnology
Healthcare
$0.80 +0.00%
+$0.00 today
- Market cap
- $56.44M
- Beta
- 1.29
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.32
52W Low $0.78High $3.82
Volume 0.43M
Average 0.81M
Income Statement
Follow revenue through to earnings.
Revenue
$100,000.00
FY 2026 · Annual
-75.0% YoYOperating Income
-$35.14M
FY 2026 · Annual
Net Income
-$33.04M
FY 2026 · Annual
Income Statement
USD
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 1.88M | 0 | 225K | 400K | 100K |
| Cost of Revenue | 3.79M | 0 | 0 | 0 | 0 |
| Gross Profit | (1.91M) | 0 | 225K | 400K | 100K |
| Gross Margin | -101.2% | — | 100.0% | 100.0% | 100.0% |
| Research & Development | 9.83M | 10.33M | 5.19M | 8.31M | 19.64M |
| Selling, General & Admin | 17.96M | 18.45M | 11.67M | 10.69M | 10.6M |
| Operating Expenses | 27.79M | 29.34M | 16.86M | 19M | 35.24M |
| Depreciation & Amortization | 3.79M | 1.38M | 1.25M | 1.13M | 646K |
| EBITDA | (25.72M) | (27.85M) | (14.02M) | (17.04M) | (32.35M) |
| EBITDA Margin | -1365.3% | — | -6231.6% | -4259.8% | -32345.0% |
| Operating Income | (29.7M) | (29.34M) | (16.63M) | (18.6M) | (35.14M) |
| Operating Margin | -1576.3% | — | -7392.9% | -4650.5% | -35141.0% |
| Interest Income | 177K | 213K | 363K | 437K | 2.15M |
| Interest Expense | 1.41M | 83K | 172K | 212K | 53K |
| Other Income / Expenses | 184K | 32K | 1.19M | 225K | 2.1M |
| Income Before Tax | (29.51M) | (29.31M) | (15.44M) | (18.38M) | (33.04M) |
| Pre-Tax Margin | -1566.5% | — | -6863.6% | -4594.3% | -33044.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.39M) | (65.01M) | (24.91M) | (18.38M) | (33.04M) |
| Net Margin | -2674.7% | — | -11069.8% | -4594.3% | -33044.0% |
| EPS (Basic) | (2,889.06) | (106.18) | (6.50) | (1.75) | (0.32) |
| EPS (Diluted) | (2,889.06) | (106.18) | (6.50) | (1.75) | (0.32) |
| 17.44K | 612.25K | 3.83M | 10.5M | 104.06M | |
| 17.44K | 612.25K | 3.83M | 10.5M | 104.06M |
IBIO Earnings Waterfall · TTM
NASDAQ:IBIO · Revenue to Net Income
Key Ratios
EPS$-0.33
Gross Margin-47.3%
Net Margin-1430.0%
P/E Ratio-5.5
P/S Ratio109.6
Analysis
$100.0K of revenue converted into -$33.0M of net income for the selected period. Gross margin is -47.3% and net margin is -1430.0%, showing how much revenue survives after costs and taxes. EPS is $-0.33, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Oct 19, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 15, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 15, 2026 |
How much revenue does IBIO generate?
iBio, Inc. (IBIO) reported $100,000.00 of revenue in fiscal 2026.
Is IBIO profitable?
iBio, Inc. (IBIO) reported -$33.04M of net income, with a net margin of -33044.0%.
Continue the stock analysis
Jump to another research area for this company.